S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.30 (-0.44%)
AAPL   137.36 (+0.01%)
MSFT   252.52 (-0.24%)
FB   193.30 (+1.05%)
GOOGL   2,175.02 (-1.48%)
AMZN   2,146.90 (+0.02%)
TSLA   663.11 (-6.53%)
NVDA   166.40 (-2.83%)
BABA   86.90 (-0.90%)
NIO   16.50 (-0.96%)
AMD   93.48 (-3.30%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.33 (+0.59%)
GE   75.30 (-0.58%)
F   12.46 (-3.04%)
DIS   102.25 (-0.86%)
AMC   12.16 (-7.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   185.99 (+1.37%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.30 (-0.44%)
AAPL   137.36 (+0.01%)
MSFT   252.52 (-0.24%)
FB   193.30 (+1.05%)
GOOGL   2,175.02 (-1.48%)
AMZN   2,146.90 (+0.02%)
TSLA   663.11 (-6.53%)
NVDA   166.40 (-2.83%)
BABA   86.90 (-0.90%)
NIO   16.50 (-0.96%)
AMD   93.48 (-3.30%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.33 (+0.59%)
GE   75.30 (-0.58%)
F   12.46 (-3.04%)
DIS   102.25 (-0.86%)
AMC   12.16 (-7.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   185.99 (+1.37%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.30 (-0.44%)
AAPL   137.36 (+0.01%)
MSFT   252.52 (-0.24%)
FB   193.30 (+1.05%)
GOOGL   2,175.02 (-1.48%)
AMZN   2,146.90 (+0.02%)
TSLA   663.11 (-6.53%)
NVDA   166.40 (-2.83%)
BABA   86.90 (-0.90%)
NIO   16.50 (-0.96%)
AMD   93.48 (-3.30%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.33 (+0.59%)
GE   75.30 (-0.58%)
F   12.46 (-3.04%)
DIS   102.25 (-0.86%)
AMC   12.16 (-7.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   185.99 (+1.37%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.30 (-0.44%)
AAPL   137.36 (+0.01%)
MSFT   252.52 (-0.24%)
FB   193.30 (+1.05%)
GOOGL   2,175.02 (-1.48%)
AMZN   2,146.90 (+0.02%)
TSLA   663.11 (-6.53%)
NVDA   166.40 (-2.83%)
BABA   86.90 (-0.90%)
NIO   16.50 (-0.96%)
AMD   93.48 (-3.30%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.33 (+0.59%)
GE   75.30 (-0.58%)
F   12.46 (-3.04%)
DIS   102.25 (-0.86%)
AMC   12.16 (-7.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   185.99 (+1.37%)
NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Forecast, Price & News

$2.25
+0.03 (+1.35%)
(As of 05/20/2022 03:59 PM ET)
Add
Compare
Today's Range
$2.22
$2.27
50-Day Range
$1.32
$3.39
52-Week Range
$0.46
$3.73
Volume
1,860 shs
Average Volume
196,337 shs
Market Capitalization
$87.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.31
30 days | 90 days | 365 days | Advanced Chart
Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Trevi Therapeutics logo

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
24
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Profitability

Net Income
$-33.94 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
20,388,000
Market Cap
$87.05 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/20/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.47 out of 5 stars

Medical Sector

155th out of 1,420 stocks

Pharmaceutical Preparations Industry

60th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -













Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

Is Trevi Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Trevi Therapeutics stock.
View analyst ratings for Trevi Therapeutics
or view top-rated stocks.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 397,500 shares, a decline of 27.6% from the April 15th total of 548,900 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 0.3 days. Currently, 11.7% of the company's shares are short sold.
View Trevi Therapeutics' Short Interest
.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Trevi Therapeutics
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, May, 12th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. During the same period last year, the business posted ($0.43) EPS.
View Trevi Therapeutics' earnings history
.

What price target have analysts set for TRVI?

2 Wall Street analysts have issued twelve-month price targets for Trevi Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Trevi Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price.
View analysts' price targets for Trevi Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trevi Therapeutics' key executives?
Trevi Therapeutics' management team includes the following people:
  • Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 57, Pay $662.64k)
  • Dr. Thomas R. Sciascia, Co-Founder & Chief Medical Officer (Age 69, Pay $476.25k)
  • Ms. Lisa Delfini, Chief Financial Officer (Age 52)
  • Mr. Christopher Galletta, Controller & Chief Accounting Officer (Age 44)
  • Mr. Frank P. Muscolo, Exec. Officer (Age 65)
  • Dr. William P. Forbes Pharm. D., Pharm.D., Chief Devel. Officer (Age 60)
  • Ms. Danine Summers, VP of Medical Affairs (Age 64)
What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include MAI Capital Management (3.98%), Vanguard Group Inc. (0.40%), Renaissance Technologies LLC (0.30%), WealthTrust Axiom LLC (0.25%), State Street Corp (0.10%) and BlackRock Inc. (0.09%). Company insiders that own Trevi Therapeutics stock include Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends for Trevi Therapeutics
.

Which institutional investors are selling Trevi Therapeutics stock?

TRVI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and BlackRock Inc..
View insider buying and selling activity for Trevi Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Trevi Therapeutics stock?

TRVI stock was acquired by a variety of institutional investors in the last quarter, including MAI Capital Management, WealthTrust Axiom LLC, State Street Corp, Virtu Financial LLC, Commonwealth Equity Services LLC, and Vanguard Group Inc..
View insider buying and selling activity for Trevi Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $2.25.

How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of $87.05 million. The company earns $-33.94 million in net income (profit) each year or ($1.350010) on an earnings per share basis.

How many employees does Trevi Therapeutics have?

Trevi Therapeutics employs 24 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 304-2499 or via email at [email protected].

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.